ArticleFrontiers in neurology2025
Somatic mutations in angiogenesis-related pathways and RNA polymerase II activity in sporadic brain arteriovenous malformations.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sporadic brain arteriovenous malformations (bAVMs) are rare vascular anomalies characterized by abnormal angiogenesis and direct arteriovenous shunting. While the VEGF pathway is well studied, the genetic landscape contributing to angiogenic dysregulation remains poorly defined. We aimed to characterize the mutational profile of resected bAVMs using a pan-cancer next-generation sequencing panel, with particular focus on angiogenesis-associated pathways and RNA Polymerase II activity. Methods: A descriptive analysis of clinical and molecular characteristics was conducted In formalin-fixed, paraffin-embedded tissue from the bAVM nidus. DNA was extracted and sequenced using the Oncomine Tumor Mutational Load Assay, covering 409 cancer-related genes. Variants were filtered for pathogenicity, allele frequency, and functional relevance. Results: Thirteen sporadic bAVMs were retrospectively analyzed. Twelve pathogenic variants were detected in 7/13 (54%) patients, with variant allele frequencies ranging from 3.61 to 50.61%. Most mutations clustered within angiogenesis-related pathways (PI3K/AKT/mTOR, RAS/MAPK), DNA repair mechanisms, and transcriptional regulators of RNA Polymerase II. Notably, six mutations involved genes with known functional links to RNA Pol II activity. These findings suggest a converging role for transcriptional dysregulation and vascular remodeling in bAVM pathogenesis. Conclusion: This study proposes a novel hypothesis implicating RNA Polymerase II-mediated transcription in the aberrant angiogenesis of bAVMs. While KRAS mutations were detected at low frequency and allele burden, other genetic alterations in DNA repair and transcriptional machinery may drive or sustain vascular instability. Further functional validation is warranted to clarify their pathogenic role and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.